The global Drugs for Schistosomiasis market generated revenue of around USD 73.4 million in 2020 and anticipated to grow at a CAGR of over 5.6% during the forecast period from 2021 to 2027 to reach around USD 103.4 million in 2027.
Schistosomiasis is a disease that affects the intestines or urogenital areas due to the infection caused by parasitic worms present in water bodies. It is mostly found in Sub-Saharan Africa, Caribbean islands, South East Asia, and the Middle east. Abdominal pain, presence of blood in urine, presence of blood in the stool, enlarged liver, and difficulty in passing urine are the major symptoms of chronic schistosomiasis. The chronic infection might lead to bladder cancer or liver fibrosis.
Key Trends in Global Drugs for Schistosomiasis Market
The increasing number of Schistosomiasis cases is driving the market growth
According to the World Health Organization, there are nearly 240 million people affected by Schistosomiasis worldwide. The major percentage of infected people are from Africa. The infection is prevailing more in the sub-tropical and tropical regions in the world. It affects communities that have no access to potable water and those communities living nearby polluted water streams. Inadequate sanitation is another reason for the spread of schistosomiasis. Lack of proper healthcare facilities prevents early detection of Schistosomiasis in many countries. Schistosomiasis is prevalent in nearly 78 countries worldwide. Pollution of water streams aids in the growth of various Schistosoma species that causes the infection.
Impact of COVID 19 on Global Drugs for Schistosomiasis Market
COVID 19 had a significant impact on global drugs for the Schistosomiasis market. Upon the spread of the pandemic, governments around the world imposed lockdowns and stringent regulations for the movement of people and goods. The drug manufacturing plants' output decreased due to the regulations initially. Hospitals focused on treating COVID 19 patients, and hence detection and treatment of diseases such as Schistosomiasis were delayed. COVID 19 caused a decrease in demand for drugs for schistosomiasis and a decline of 2.5% in total revenue generated by the global drugs for the schistosomiasis market when compared to 2019.
To Understand How Covid-19 Impact Is Covered in This Report - https://www.credenceresearch.com/report/drugs-for-schistosomiasis-market
Global Drugs for Schistosomiasis Market by Drug Type Insights
Artemisinins, Biltricide, Corticosteroids, Metrifonate, Trioxolanes, Praziquantel, and Oxamniquine are the major drugs for schistosomiasis. With nearly 24.3% share, Praziquantel accounted for the majority share of the total revenue generated by the global Schistosomiasis market in 2020.
Praziquantel dominate the global Drugs for Schistosomiasis market
Global Drugs for Schistosomiasis Market by Application Insights
Schistosoma Haematobium, Schistosoma Japonicum, and Schistosoma Mansoni, mostly causes Schistosomiasis. These three species accounted for the majority of the application of drugs for schistosomiasis in 2020. The other three species are limited to certain geographical areas.
Global Drugs for Schistosomiasis Market by Distribution Channel Insights
Hospital pharmacy, online pharmacy, and retail pharmacy are the three major distribution channels in the drugs for the schistosomiasis market. With nearly 32.1 %, hospital pharmacy accounted for the majority of revenue generated in the market, as patients rely heavily on it for the drugs, upon receiving a prescription from the doctors.
Global Drugs for Schistosomiasis Market by Regional Insights
Africa was the largest market of drugs for Schistosomiasis in 2020. They accounted for nearly 28.9% share in overall revenue generated globally. There are nearly 120 million people in sub-Saharan Africa with symptoms related to schistosomiasis. Nearly 20 million people are having chronic conditions. Lack of access to clean water and the presence of polluted water sources drives the infection rate of schistosomiasis in Africa. The Middle East has a significant number of schistosomiasis patients. The number of schistosomiasis patients is increasing in countries with huge populations in Latin America. The presence of a huge number of polluted water streams and living populations near waterbodies drive the growth of schistosomiasis patients in the Asia-Pacific region. The up-gradation of the healthcare systems in Asia-pacific countries is improving the detection of infection.
Global Drugs for Schistosomiasis Market Competitive Landscape
Most prominent players in the global drugs for schistosomiasis include Bayer AG, Chandra Bhagat Pharma Ltd, EIPICO, Merck & Co Inc, Pfizer Inc, Par Pharmaceutical Inc, Samarth Pharma Pvt Ltd, Sanofi SA, Shin Poong Pharm Co Ltd, and Taj Pharmaceuticals Ltd among others. The report covers very detailed profiles of these key players.
Market Segmentation
Global Drugs for Schistosomiasis Market by Drug Type, 2015 - 2027
- Artemisinins
- Biltricide
- Corticosteroids
- Metrifonate
- Trioxolanes
- Praziquantel
- Oxamniquine
- Others
Global Drugs for Schistosomiasis Market by Application, 2015 - 2027
- Schistosoma Guineensis
- Schistosoma Haematobium
- Schistosoma Intercalatum
- Schistosoma Japonicum
- Schistosoma Mansoni
- Schistosoma Mekongi
Global Drugs for Schistosomiasis Market by Distribution Channel, 2015 – 2027
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Global Drugs for Schistosomiasis Market by Region, 2015 - 2027
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Global Drugs for Schistosomiasis Market: Key Players
- Bayer AG
- Chandra Bhagat Pharma Ltd
- EIPICO
- Merck & Co Inc
- Pfizer Inc
- Par Pharmaceutical Inc
- Samarth Pharma Pvt Ltd
- Sanofi SA
- Shin Poong Pharm Co Ltd
. Taj Pharmaceuticals Ltd
Get extensive insights into the “Drugs for Schistosomiasis market” Request sample copy@ https://www.credenceresearch.com/sample-request/60309
DoC: https://issuu.com/robsonspot/docs/drugs_for_schistosomiasis_market.docx
About Us
Credence Research is a worldwide market research and counseling firm that serves driving organizations, governments, non-legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives.
Media Contact
Name: Chris Smith
Address: 105 N 1st ST #429,
SAN JOSE, CA 95103 US
(US/CANADA) Ph.: +1-800-361-8290
E-mail: sales@credenceresearch.com
Comments